Session

Overview: Recent years have seen an increasing use of radiotherapy in combination with novel treatment modalities such as molecular targeted agents. However, little is known about the differential response of multiple treatment modalities on normal tissue and the impact this might have on the development of early and late radiation-related side effects. This symposium offers an overview of: • A selection of preclinical studies focusing on the combination of radiation with molecular therapies such as anti-angiogenic drugs and DNA damage response inhibitors. • The development of in vitro and in vivo normal tissue models, with an emphasis on lung, to evaluate both tumour control and normal tissue damage.